Chinese herbal medicine combined with entecavir to reduce the off-therapy recurrence risk in HBeAg-positive chronic hepatitis B patients: a multicener, double-blind, randomized controlled trial in China

BACKGROUND: Nucleos(t)ide analogues (NAs) are the first-line option against chronic hepatitis B (CHB). NAs produce potent suppression of viral replication with a small chance of HBsAg seroclearance and a high risk of virological relapse after discontinuation. The combined therapy of NAs plus traditi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaoke, Zhang, Ludan, Qiu, Mei, Huang, Yi, Xiao, Huanming, Lu, Bingjiu, Jiang, Yuyong, Long, Fuli, Lin, Hui, He, Jinyu, Wu, Qikai, Zhang, Mingxiang, Wang, Li, Zhu, Xiaoning, Gong, Man, Sun, Xuehua, Sun, Jianguang, Sun, Fengxia, Lu, Wei, Xu, Weihua, Chen, Guang, Li, Zhiguo, Gan, Danan, Yang, Xianzhao, Du, Hongbo, Ye, Yong’an
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422608/
https://www.ncbi.nlm.nih.gov/pubmed/32787905
http://dx.doi.org/10.1186/s13063-020-04417-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422608/
https://www.ncbi.nlm.nih.gov/pubmed/32787905
http://dx.doi.org/10.1186/s13063-020-04417-9

Ejemplares similares